v3.26.1
COMMITMENTS
 12 Months Ended
Dec. 31, 2025
Notes and other explanatory information [abstract]  
COMMITMENTS

26 COMMITMENTS

 

  (a) Operating lease commitments

 

   2023   2024   2025 
   S$   S$   S$ 
                
Low value leases   1,703    3,215    5,267 

 

The Group has elected not to recognize right-of-use assets and lease liabilities for short-term leases that have lease terms of 12 months or less and leases of low value leases. Lease payments relating to these leases are charged to profit or loss on a straight-line basis over the lease term.

 

  (b) Capital commitments

 

Capital expenditures contracted for at the balance sheet date but not recognized in the financial statements are as follows:

 

   2023   2024   2025 
   S$   S$   S$ 
             
Purchase of a property in Malaysia   387,720    -    - 
Loan to a third party*   1,000,000    500,000    500,000 

 

* The Group embarked on its strategy in People’s Republic of China via a collaborative effort on using the CTM-GDT for cancer immunotherapy. As such, the Group committed this loan to a third party for the purpose of conducting an investigator initiated clinical trial through local partners in Chongqing, one of the most populous regions in People’s Republic of China.

 

  (c) Other commitments

 

The Group entered into an exclusive, worldwide, non-sublicensable, non-transferable and revocable-for-cause license with an independent company for the NKG2DL-targeting CAR-gamma delta T cell and iPSC-gdNKT cell technology. As of December 31, 2025, the total future minimum payments under non-cancellable licensing agreements are as follows:

 

   2023   2024   2025 
   S$   S$   S$ 
             
Within 1 year   5,885    12,333    5,067 
After 1 year but within 5 years   47,960    43,600    43,600 
Over 5 years   106,457    87,200    87,200 
Total   160,302    143,133    135,867 

 

 

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2023, 2024 and 2025